the cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus的成本效益和价值三个接种流感疫苗剂量策略信息为个人与人类免疫缺陷病毒.pdfVIP

The Cost-Effectiveness and Value of Information of Three Influenza Vaccination Dosing Strategies for Individuals with Human Immunodeficiency Virus 1 1 1 1,2 1,3 Bohdan Nosyk , Behnam Sharif , Huiying Sun , Curtis Cooper , Aslam H. Anis *, on behalf of the CIHR Canadian HIV Trials Network Influenza Vaccine Research Group 1 CIHR Canadian HIV Trials Network, Vancouver, British Columbia, Canada, 2 Division of Infectious Diseases, University of Ottawa, Ottawa, Canada, 3 School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada Abstract Background: Influenza vaccine immunogenicity is diminished in patients living with HIV/AIDS. We evaluated the cost- effectiveness and expected value of perfect information (EVPI) of three alternative influenza vaccine dosing strategies intended to increase immunogenicity in those patients. Methods: A randomized, multi-centered, controlled, vaccine trial was conducted at 12 CIHR Canadian HIV Trials Network sites. Three dosing strategies with seasonal, inactivated trivalent, non-adjuvanted intramuscular vaccine were used in HIV infected adults: two standard doses over 28 days (Strategy A), two double doses over 28 days (Strategy B) and a single standard dose of influenza vaccine (Strategy C), administered prior to the 2008 influenza season. The comparator in our analysis was practice in the previous year, in which 82.8% of HIV/AIDS received standard-dose vaccination (Strategy D). A Markov cohort model was developed to estimate the monthly probability of Influenza-like Illness (ILI) over one influenza season. Costs and quality-adjusted life years, extrapolated to the lifetime of the hypothetical study cohorts, were estimated